Genmab A/S (GEN.CO) Announces New Study of Daratumumab in Double Refractory Multiple Myeloma
9/10/2013 9:14:15 AM
Copenhagen, Denmark; September 10, 2013 – Genmab A/S (OMX: GEN) announced today that its partner, Janssen Biotech, Inc. (“Janssen”) will start a new Phase II study of daratumumab in multiple myeloma. The Phase II study is designed in 2 parts in multiple myeloma patients who have received at least three different lines of therapy including both a proteasome inhibitor and an immunomodulatory agent (IMiD) or who are double refractory to a proteasome inhibitor and an IMiD. This is the same indication for which daratumumab was granted Breakthrough Therapy Designation from the FDA in May 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by